Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Preclinical Drug Metabolism, Pharmacokinetic, and Pharmacodynamic Profiles of Ivosidenib, an Inhibitor of Mutant Isocitrate Dehydrogenase 1 for Treatment of Isocitrate Dehydrogenase 1-Mutant Malignancies

Yue Chen, Nelamangala V. Nagaraja, Bin Fan, Luke Utley, Rene M. Lemieux, Janeta Popovici-Muller, Lenny Dang, Hyeryun Kim, Liping Yan, Shin-San M. Su, Scott A. Biller and Hua Yang
Drug Metabolism and Disposition October 2021, 49 (10) 870-881; DOI: https://doi.org/10.1124/dmd.120.000234
Yue Chen
Agios Pharmaceuticals, Inc., Cambridge, Massachusetts (Y.C., N.V.N., B.F., L.U., R.M.L., J.P.-M., L.D., H.K., S.-S.M.S., S.A.B., H.Y.); ChemPartner, Shanghai, China (L.Y.); Servier Pharmaceuticals LLC, Boston, Massachusetts (N.V.N.); KLUS Pharma, Cranbury, New Jersey (B.F.); Ribon Therapeutics, Cambridge, Massachusetts (L.U.); Faze Medicines, Inc., Cambridge, Massachusetts (R.M.L.); Rectify Pharmaceuticals, Cambridge, Massachusetts (J.P.-M.); Volastra Therapeutics, Inc., New York, New York (S.-S.M.S.); and Disc Medicine, Cambridge, Massachusetts (H.Y.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nelamangala V. Nagaraja
Agios Pharmaceuticals, Inc., Cambridge, Massachusetts (Y.C., N.V.N., B.F., L.U., R.M.L., J.P.-M., L.D., H.K., S.-S.M.S., S.A.B., H.Y.); ChemPartner, Shanghai, China (L.Y.); Servier Pharmaceuticals LLC, Boston, Massachusetts (N.V.N.); KLUS Pharma, Cranbury, New Jersey (B.F.); Ribon Therapeutics, Cambridge, Massachusetts (L.U.); Faze Medicines, Inc., Cambridge, Massachusetts (R.M.L.); Rectify Pharmaceuticals, Cambridge, Massachusetts (J.P.-M.); Volastra Therapeutics, Inc., New York, New York (S.-S.M.S.); and Disc Medicine, Cambridge, Massachusetts (H.Y.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bin Fan
Agios Pharmaceuticals, Inc., Cambridge, Massachusetts (Y.C., N.V.N., B.F., L.U., R.M.L., J.P.-M., L.D., H.K., S.-S.M.S., S.A.B., H.Y.); ChemPartner, Shanghai, China (L.Y.); Servier Pharmaceuticals LLC, Boston, Massachusetts (N.V.N.); KLUS Pharma, Cranbury, New Jersey (B.F.); Ribon Therapeutics, Cambridge, Massachusetts (L.U.); Faze Medicines, Inc., Cambridge, Massachusetts (R.M.L.); Rectify Pharmaceuticals, Cambridge, Massachusetts (J.P.-M.); Volastra Therapeutics, Inc., New York, New York (S.-S.M.S.); and Disc Medicine, Cambridge, Massachusetts (H.Y.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luke Utley
Agios Pharmaceuticals, Inc., Cambridge, Massachusetts (Y.C., N.V.N., B.F., L.U., R.M.L., J.P.-M., L.D., H.K., S.-S.M.S., S.A.B., H.Y.); ChemPartner, Shanghai, China (L.Y.); Servier Pharmaceuticals LLC, Boston, Massachusetts (N.V.N.); KLUS Pharma, Cranbury, New Jersey (B.F.); Ribon Therapeutics, Cambridge, Massachusetts (L.U.); Faze Medicines, Inc., Cambridge, Massachusetts (R.M.L.); Rectify Pharmaceuticals, Cambridge, Massachusetts (J.P.-M.); Volastra Therapeutics, Inc., New York, New York (S.-S.M.S.); and Disc Medicine, Cambridge, Massachusetts (H.Y.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rene M. Lemieux
Agios Pharmaceuticals, Inc., Cambridge, Massachusetts (Y.C., N.V.N., B.F., L.U., R.M.L., J.P.-M., L.D., H.K., S.-S.M.S., S.A.B., H.Y.); ChemPartner, Shanghai, China (L.Y.); Servier Pharmaceuticals LLC, Boston, Massachusetts (N.V.N.); KLUS Pharma, Cranbury, New Jersey (B.F.); Ribon Therapeutics, Cambridge, Massachusetts (L.U.); Faze Medicines, Inc., Cambridge, Massachusetts (R.M.L.); Rectify Pharmaceuticals, Cambridge, Massachusetts (J.P.-M.); Volastra Therapeutics, Inc., New York, New York (S.-S.M.S.); and Disc Medicine, Cambridge, Massachusetts (H.Y.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Janeta Popovici-Muller
Agios Pharmaceuticals, Inc., Cambridge, Massachusetts (Y.C., N.V.N., B.F., L.U., R.M.L., J.P.-M., L.D., H.K., S.-S.M.S., S.A.B., H.Y.); ChemPartner, Shanghai, China (L.Y.); Servier Pharmaceuticals LLC, Boston, Massachusetts (N.V.N.); KLUS Pharma, Cranbury, New Jersey (B.F.); Ribon Therapeutics, Cambridge, Massachusetts (L.U.); Faze Medicines, Inc., Cambridge, Massachusetts (R.M.L.); Rectify Pharmaceuticals, Cambridge, Massachusetts (J.P.-M.); Volastra Therapeutics, Inc., New York, New York (S.-S.M.S.); and Disc Medicine, Cambridge, Massachusetts (H.Y.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lenny Dang
Agios Pharmaceuticals, Inc., Cambridge, Massachusetts (Y.C., N.V.N., B.F., L.U., R.M.L., J.P.-M., L.D., H.K., S.-S.M.S., S.A.B., H.Y.); ChemPartner, Shanghai, China (L.Y.); Servier Pharmaceuticals LLC, Boston, Massachusetts (N.V.N.); KLUS Pharma, Cranbury, New Jersey (B.F.); Ribon Therapeutics, Cambridge, Massachusetts (L.U.); Faze Medicines, Inc., Cambridge, Massachusetts (R.M.L.); Rectify Pharmaceuticals, Cambridge, Massachusetts (J.P.-M.); Volastra Therapeutics, Inc., New York, New York (S.-S.M.S.); and Disc Medicine, Cambridge, Massachusetts (H.Y.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hyeryun Kim
Agios Pharmaceuticals, Inc., Cambridge, Massachusetts (Y.C., N.V.N., B.F., L.U., R.M.L., J.P.-M., L.D., H.K., S.-S.M.S., S.A.B., H.Y.); ChemPartner, Shanghai, China (L.Y.); Servier Pharmaceuticals LLC, Boston, Massachusetts (N.V.N.); KLUS Pharma, Cranbury, New Jersey (B.F.); Ribon Therapeutics, Cambridge, Massachusetts (L.U.); Faze Medicines, Inc., Cambridge, Massachusetts (R.M.L.); Rectify Pharmaceuticals, Cambridge, Massachusetts (J.P.-M.); Volastra Therapeutics, Inc., New York, New York (S.-S.M.S.); and Disc Medicine, Cambridge, Massachusetts (H.Y.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Liping Yan
Agios Pharmaceuticals, Inc., Cambridge, Massachusetts (Y.C., N.V.N., B.F., L.U., R.M.L., J.P.-M., L.D., H.K., S.-S.M.S., S.A.B., H.Y.); ChemPartner, Shanghai, China (L.Y.); Servier Pharmaceuticals LLC, Boston, Massachusetts (N.V.N.); KLUS Pharma, Cranbury, New Jersey (B.F.); Ribon Therapeutics, Cambridge, Massachusetts (L.U.); Faze Medicines, Inc., Cambridge, Massachusetts (R.M.L.); Rectify Pharmaceuticals, Cambridge, Massachusetts (J.P.-M.); Volastra Therapeutics, Inc., New York, New York (S.-S.M.S.); and Disc Medicine, Cambridge, Massachusetts (H.Y.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shin-San M. Su
Agios Pharmaceuticals, Inc., Cambridge, Massachusetts (Y.C., N.V.N., B.F., L.U., R.M.L., J.P.-M., L.D., H.K., S.-S.M.S., S.A.B., H.Y.); ChemPartner, Shanghai, China (L.Y.); Servier Pharmaceuticals LLC, Boston, Massachusetts (N.V.N.); KLUS Pharma, Cranbury, New Jersey (B.F.); Ribon Therapeutics, Cambridge, Massachusetts (L.U.); Faze Medicines, Inc., Cambridge, Massachusetts (R.M.L.); Rectify Pharmaceuticals, Cambridge, Massachusetts (J.P.-M.); Volastra Therapeutics, Inc., New York, New York (S.-S.M.S.); and Disc Medicine, Cambridge, Massachusetts (H.Y.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Scott A. Biller
Agios Pharmaceuticals, Inc., Cambridge, Massachusetts (Y.C., N.V.N., B.F., L.U., R.M.L., J.P.-M., L.D., H.K., S.-S.M.S., S.A.B., H.Y.); ChemPartner, Shanghai, China (L.Y.); Servier Pharmaceuticals LLC, Boston, Massachusetts (N.V.N.); KLUS Pharma, Cranbury, New Jersey (B.F.); Ribon Therapeutics, Cambridge, Massachusetts (L.U.); Faze Medicines, Inc., Cambridge, Massachusetts (R.M.L.); Rectify Pharmaceuticals, Cambridge, Massachusetts (J.P.-M.); Volastra Therapeutics, Inc., New York, New York (S.-S.M.S.); and Disc Medicine, Cambridge, Massachusetts (H.Y.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hua Yang
Agios Pharmaceuticals, Inc., Cambridge, Massachusetts (Y.C., N.V.N., B.F., L.U., R.M.L., J.P.-M., L.D., H.K., S.-S.M.S., S.A.B., H.Y.); ChemPartner, Shanghai, China (L.Y.); Servier Pharmaceuticals LLC, Boston, Massachusetts (N.V.N.); KLUS Pharma, Cranbury, New Jersey (B.F.); Ribon Therapeutics, Cambridge, Massachusetts (L.U.); Faze Medicines, Inc., Cambridge, Massachusetts (R.M.L.); Rectify Pharmaceuticals, Cambridge, Massachusetts (J.P.-M.); Volastra Therapeutics, Inc., New York, New York (S.-S.M.S.); and Disc Medicine, Cambridge, Massachusetts (H.Y.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 49 (10)
Drug Metabolism and Disposition
Vol. 49, Issue 10
1 Oct 2021
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Preclinical Drug Metabolism, Pharmacokinetic, and Pharmacodynamic Profiles of Ivosidenib, an Inhibitor of Mutant Isocitrate Dehydrogenase 1 for Treatment of Isocitrate Dehydrogenase 1-Mutant Malignancies
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Preclinical Drug Metabolism and PK Profile of Ivosidenib

Yue Chen, Nelamangala V. Nagaraja, Bin Fan, Luke Utley, Rene M. Lemieux, Janeta Popovici-Muller, Lenny Dang, Hyeryun Kim, Liping Yan, Shin-San M. Su, Scott A. Biller and Hua Yang
Drug Metabolism and Disposition October 1, 2021, 49 (10) 870-881; DOI: https://doi.org/10.1124/dmd.120.000234

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Preclinical Drug Metabolism and PK Profile of Ivosidenib

Yue Chen, Nelamangala V. Nagaraja, Bin Fan, Luke Utley, Rene M. Lemieux, Janeta Popovici-Muller, Lenny Dang, Hyeryun Kim, Liping Yan, Shin-San M. Su, Scott A. Biller and Hua Yang
Drug Metabolism and Disposition October 1, 2021, 49 (10) 870-881; DOI: https://doi.org/10.1124/dmd.120.000234
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Human ADME Properties of Abrocitinib
  • MSCs Pharmacokinetics under liver diseases
  • In Vitro-In Vivo Extrapolation Using Empirical Scaling
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics